Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy

Table 4 Multivariate analysis of factors associated with overall survival in patients who underwent potentially curative resection for colorectal cancer liver metastases stratified for patients’ MSKCC clinical risk score

Variable	Comparison	Hazard ratio	95% CI	PValue
MSKCC clinical risk score ≤ 2
Age	-	1.01	0.99 – 1.04	0.20
Distribution of metastasis	Bilobar vs. unilobar	1.80	1.12 – 2.92	0.01
Initial stage of disease (UICC)				0.41
	1	Reference
	2	1.96	0.80 – 4.81	0.13
	3	1.92	0.80 – 4.59	0.14
	4	1.52	0.60 – 3.83	0.36
Adjuvant chemotherapy	Adjuvant CTx vs. no adjuvant CTx	0.90	0.57 – 1.43	0.67
MSKCC clinical risk score > 2
Age	-	1.00	0.98 – 1.03	0.61
Distribution of metastasis	Bilobar vs. unilobar	1.65	0.98 – 2.77	0.06
Initial stage of disease (UICC)				0.21
	1	Reference
	2	0.21	0.02 – 2.27	0.20
	3	0.60	0.07 – 4.79	0.63
	4	0.38	0.05 – 3.03	0.36
Adjuvant chemotherapy	Adjuvant CTx vs. no adjuvant CTx	0.40	0.23 – 0.70	0.001

ISSN: 1471-2407